Overview of HIV Drugs MarketThe Global HIV Drugs Market is valued at USD 34.75 Billion in 2024 and is projected to reach a ...

Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations ...

Global HIV Drugs Market is valued at approximately USD 34.28 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2024-2032. Read the Market ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Police in Wigan seized a quantity of drugs class A after receiving a tip-off from the public. Officers stopped and searched a car on Flapper Fold Lane in Atherton on Wednesday (March 19 ...

Please note that classification priorities can change quickly, and the expected dates of completion are only indicative at the time of publication. There is high demand for classification assessments, ...

GILD boasts a market-leading portfolio of HIV treatments both for treating the disease and prevention. The company has two drugs for HIV prevention in its portfolio – Descovy and Truvada.

The National Agency for the Control of AIDS (NACA) has assured Nigerians, particularly those living with HIV, that there is no shortage of antiretroviral drugs in the country. In response to ...

Also, the National Agency for the Control of AIDS (NACA) reassured Nigerians, particularly those living with HIV, that the country has a steady supply of antiretroviral drugs. Speaking with ...

The National Agency for the Control of AIDS on Wednesday reassured Nigerians, particularly those living with HIV, that the country has a steady supply of antiretroviral drugs. This assurance came ...